Premium
Intravenous treosulfan versus intravenous treosulfan plus cisplatinum in advanced ovarian carcinoma
Author(s) -
MASDING J.,
SARKAR T. K.,
WHITE W. F.,
BARLEY V. L.,
CHAWLA S. L.,
BOESEN E.,
ROSTOM A. Y.,
MENDAY A. P.
Publication year - 1990
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.1990.tb01813.x
Subject(s) - treosulfan , medicine , toxicity , surgery , oncology , urology , chemotherapy , busulfan , cyclophosphamide
Summary. In a prospective, multicentre, randomized trial, the efficacy and tolerance of treosulfan alone was compared with that of treosulfan plus cisplatinum in 135 women with advanced ovarian carcinoma. No statistically significant difference was found between the two treatments in terms of median survival. Combined treatment was associated with significantly greater side‐effects and haematological toxicity. Optimal survival with minimal toxicity can be achieved by using treosulfan alone in patients (mainly stages Ic or II) with minimal postoperative residual disease. Patients (likely to be stage III or IV) with greater residual disease should receive treosulfan plus cisplatinum.